Immune checkpoint agents targeting the PD-1/PD-L1 signaling pathway have been successfully applied to the treatment of different types of malignant tumors, including non-small-cell lung cancer [18], kidney cancer [19], bladder cancer [20] and malignant melanoma [21]. Here, PDCD1 is linked to kidney cancer.